89Zr-atezolizumab

89Zr-atezolizumab is an investigational radiopharmaceutical designed for molecular imaging of Programmed Death-Ligand 1 (PD-L1) expression. It consists of the humanized IgG1 monoclonal antibody atezolizumab radiolabeled with the positron-emitting isotope Zirconium-89 (89Zr), typically via a chelator such as desferrioxamine (DFO). By binding specifically to PD-L1 on tumor cells and tumor-infiltrating immune cells, the tracer enables the non-invasive, whole-body assessment of PD-L1 biodistribution and spatial heterogeneity using Positron Emission Tomography (PET) scanning. This diagnostic tool is primarily used in clinical research to optimize patient selection for immune checkpoint inhibitor (ICI) therapies, monitor target engagement over time, and investigate mechanisms of primary and acquired resistance in various malignancies, including lymphoma and breast cancer.

Other names

89Zr-labeled atezolizumabZirconium Zr 89 atezolizumab[89Zr]atezolizumab89Zr-DFO-atezolizumab89Zr-desferrioxamine-atezolizumab